Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 1
R&D Momentum
18/100
Pipeline Velocity
0/100
Trial Completion Rate
91/100
Pipeline Concentration
100/100
Pipeline Freshness
74/100
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
MS Contin — AVINZA
Application NDA021260 (NDA)
Amicar — AMICAR
Application NDA015197 (NDA)
MS Contin — DEPODUR
Application NDA021671 (NDA)
Xopenex Hfa — XOPENEX HFA
Application NDA021730 (NDA)
MS Contin — KADIAN
Application NDA020616 (NDA)
MS Contin — MORPHINE SULFATE
Application NDA022207 (NDA)
MS Contin — MORPHINE SULFATE
Application NDA022195 (NDA)
Codeine Sulfate — CODEINE SULFATE
Application NDA022402 (NDA)
MS Contin — MORPHINE SULFATE
Application NDA202515 (NDA)
Codeine Sulfate — CODEINE SULFATE
Application NDA202245 (NDA)
MS Contin — MORPHINE SULFATE
Application NDA201517 (NDA)
MS Contin — MORPHINE SULFATE
Application NDA204223 (NDA)
MS Contin — MORPHABOND ER
Application NDA206544 (NDA)
MS Contin — ARYMO ER
Application NDA208603 (NDA)
Vancocin — VANCOMYCIN HYDROCHLORIDE
Application NDA209481 (NDA)
Vancocin — FIRVANQ KIT
Application NDA208910 (NDA)
Vancocin — TYZAVAN
Application NDA211962 (NDA)
Vancocin — VANCOMYCIN
Application NDA213895 (NDA)
Anectine — SUCCINYLCHOLINE CHLORIDE
Application NDA215143 (NDA)
Vancocin — VANCOMYCIN HYDROCHLORIDE
Application NDA210274 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)